SPERO THERAPEUTICS INC (SPRO) Fundamental Analysis & Valuation

NASDAQ:SPRO • US84833T1034

Current stock price

2.43 USD
-0.02 (-0.82%)
At close:
2.38 USD
-0.05 (-2.06%)
After Hours:

This SPRO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SPRO Profitability Analysis

1.1 Basic Checks

  • SPRO had positive earnings in the past year.
  • SPRO had a negative operating cash flow in the past year.
  • In the past 5 years SPRO reported 4 times negative net income.
  • In the past 5 years SPRO always reported negative operating cash flow.
SPRO Yearly Net Income VS EBIT VS OCF VS FCFSPRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -80.92%, SPRO is doing worse than 67.89% of the companies in the same industry.
  • SPRO has a Return On Equity of -165.46%. This is in the lower half of the industry: SPRO underperforms 65.76% of its industry peers.
Industry RankSector Rank
ROA -80.92%
ROE -165.46%
ROIC N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
SPRO Yearly ROA, ROE, ROICSPRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

  • SPRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRO Yearly Profit, Operating, Gross MarginsSPRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SPRO Health Analysis

2.1 Basic Checks

  • SPRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SPRO Yearly Shares OutstandingSPRO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SPRO Yearly Total Debt VS Total AssetsSPRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -10.65, we must say that SPRO is in the distress zone and has some risk of bankruptcy.
  • SPRO's Altman-Z score of -10.65 is on the low side compared to the rest of the industry. SPRO is outperformed by 73.50% of its industry peers.
  • SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.65
ROIC/WACCN/A
WACC9.21%
SPRO Yearly LT Debt VS Equity VS FCFSPRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • SPRO has a Current Ratio of 3.83. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
  • SPRO has a Current ratio (3.83) which is in line with its industry peers.
  • A Quick Ratio of 3.83 indicates that SPRO has no problem at all paying its short term obligations.
  • SPRO has a Quick ratio (3.83) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.83
Quick Ratio 3.83
SPRO Yearly Current Assets VS Current LiabilitesSPRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SPRO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 109.45% over the past year.
EPS 1Y (TTM)109.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%239.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%174.53%

3.2 Future

  • The Earnings Per Share is expected to decrease by -29.84% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 37.19% on average over the next years. This is a very strong growth
EPS Next Y469.5%
EPS Next 2Y-178.93%
EPS Next 3Y-125.29%
EPS Next 5Y-29.84%
Revenue Next Year-96.86%
Revenue Next 2Y-64.58%
Revenue Next 3Y9.08%
Revenue Next 5Y37.19%

3.3 Evolution

SPRO Yearly Revenue VS EstimatesSPRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
SPRO Yearly EPS VS EstimatesSPRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

5

4. SPRO Valuation Analysis

4.1 Price/Earnings Ratio

  • SPRO is valuated rather expensively with a Price/Earnings ratio of 20.25.
  • Compared to the rest of the industry, the Price/Earnings ratio of SPRO indicates a rather cheap valuation: SPRO is cheaper than 93.23% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.60. SPRO is valued slightly cheaper when compared to this.
  • SPRO is valuated cheaply with a Price/Forward Earnings ratio of 3.56.
  • 98.84% of the companies in the same industry are more expensive than SPRO, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of SPRO to the average of the S&P500 Index (22.84), we can say SPRO is valued rather cheaply.
Industry RankSector Rank
PE 20.25
Fwd PE 3.56
SPRO Price Earnings VS Forward Price EarningsSPRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRO Per share dataSPRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

  • SPRO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • SPRO's earnings are expected to decrease with -125.29% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y-178.93%
EPS Next 3Y-125.29%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SPRO Dividend Analysis

5.1 Amount

  • SPRO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SPRO Fundamentals: All Metrics, Ratios and Statistics

SPERO THERAPEUTICS INC

NASDAQ:SPRO (4/2/2026, 8:00:03 PM)

After market: 2.38 -0.05 (-2.06%)

2.43

-0.02 (-0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26
Earnings (Next)05-11
Inst Owners33.58%
Inst Owner Change87.04%
Ins Owners2.04%
Ins Owner Change1.55%
Market Cap136.91M
Revenue(TTM)N/A
Net Income(TTM)-43.84M
Analysts43.33
Price Target4.08 (67.9%)
Short Float %1.24%
Short Ratio1.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)70.64%
Min EPS beat(2)49.02%
Max EPS beat(2)92.26%
EPS beat(4)3
Avg EPS beat(4)44.13%
Min EPS beat(4)-20.18%
Max EPS beat(4)92.26%
EPS beat(8)6
Avg EPS beat(8)100.4%
EPS beat(12)10
Avg EPS beat(12)186.6%
EPS beat(16)11
Avg EPS beat(16)138.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 20.25
Fwd PE 3.56
P/S 3.38
P/FCF N/A
P/OCF N/A
P/B 5.17
P/tB 5.17
EV/EBITDA N/A
EPS(TTM)0.12
EY4.94%
EPS(NY)0.68
Fwd EY28.12%
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.72
BVpS0.47
TBVpS0.47
PEG (NY)0.04
PEG (5Y)N/A
Graham Number1.13
Profitability
Industry RankSector Rank
ROA -80.92%
ROE -165.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.83
Quick Ratio 3.83
Altman-Z -10.65
F-Score3
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)109.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%239.47%
EPS Next Y469.5%
EPS Next 2Y-178.93%
EPS Next 3Y-125.29%
EPS Next 5Y-29.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%174.53%
Revenue Next Year-96.86%
Revenue Next 2Y-64.58%
Revenue Next 3Y9.08%
Revenue Next 5Y37.19%
EBIT growth 1Y-3984.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-195.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-195.49%
OCF growth 3YN/A
OCF growth 5YN/A

SPERO THERAPEUTICS INC / SPRO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SPERO THERAPEUTICS INC (SPRO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SPRO.


Can you provide the valuation status for SPERO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 5 / 10 to SPERO THERAPEUTICS INC (SPRO). This can be considered as Fairly Valued.


How profitable is SPERO THERAPEUTICS INC (SPRO) stock?

SPERO THERAPEUTICS INC (SPRO) has a profitability rating of 0 / 10.


Can you provide the financial health for SPRO stock?

The financial health rating of SPERO THERAPEUTICS INC (SPRO) is 6 / 10.


Can you provide the expected EPS growth for SPRO stock?

The Earnings per Share (EPS) of SPERO THERAPEUTICS INC (SPRO) is expected to grow by 469.5% in the next year.